REGENERATE – AMI

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

EU CTR

Registry ID

EUCTR2010-021277-36-DK

Enrollment

100

Registered

2011-02-17

Start date

2011-04-19

Completion date

Unknown

Last updated

2017-12-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Patients with acute ST-elevation myocardial infarction will be treated with progenitor cells after acute revascularisation. MedDRA version: 14.1 Level: LLT Classification code 10028597 Term: Myocardial infarction acute System Organ Class: 10007541 - Cardiac disorders

Interventions

Product Name: Progenitor cells Product Code: Progenitor cells Pharmaceutical Form: Injection* Pharmaceutical form of the placebo: Injection* Route of administration of the placebo: Intraarterial use

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Acute ST-elevation infarction in the left anterior descendens artery treated acutely with percutaneous balloon angioplasty or stent implantation. Are the trial subjects under 18? no Number of subjects for this age range: F.1.2 Adults (18-64 years) yes F.1.2.1 Number of subjects for this age range F.1.3 Elderly (>=65 years) yes F.1.3.1 Number of subjects for this age range

Exclusion criteria

Exclusion criteria: Active infection Neoplasma Cerebrovascular infarction Reduced kidney function

Design outcomes

Primary

Measure	Time frame
Main Objective: To improve post-infarction myocardial function;Secondary Objective: To improve myocardial perfusion and infarct size.;Primary end point(s): Left ventricular ejection fraction at 12 months follow-up	—

Countries

Denmark

Outcome results

None listed

Source: EU CTR (via WHO ICTRP) · Data processed: Feb 4, 2026